Floatz logo

Hycamtin

BRCA 2 Gene Mutation

AstraZenecaPhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the BRCA 2 Gene Mutation cohort.

Asset / SponsorPhaseRating
Talzenna
Brown University
Phase 3BB
Inno-206
AstraZeneca
Phase 3BB
sc10914
Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Phase 2CCC

Same molecule, other indications

Hycamtin is also rated in:

primary peritoneal carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →
non-small cell lung carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →